1
00:00:02,759 --> 00:00:07,240
Speaker 1: Bloomberg Audio Studios, podcasts, radio news.

2
00:00:08,080 --> 00:00:10,319
Speaker 2: Let's switch gears here and talk about bird flu because

3
00:00:10,360 --> 00:00:13,960
Speaker 2: Zoettas has been granted a conditional license from the USDA

4
00:00:14,040 --> 00:00:17,160
Speaker 2: for its avian flu vaccine. Since February twenty twenty two,

5
00:00:17,160 --> 00:00:19,560
Speaker 2: more than one hundred and fifty million birds have been

6
00:00:19,600 --> 00:00:22,560
Speaker 2: affected in the US, causing egg prices to surge to

7
00:00:22,640 --> 00:00:26,040
Speaker 2: all time highs. Joining us now is the CEO of Zoettis,

8
00:00:26,120 --> 00:00:28,760
Speaker 2: Kristen pak Christen, It's great to see you in studio.

9
00:00:28,840 --> 00:00:30,520
Speaker 1: First of all, Oh, it's very nice to be back

10
00:00:30,520 --> 00:00:31,280
Speaker 1: in studio with you all.

11
00:00:31,520 --> 00:00:35,080
Speaker 2: So let's talk about your vaccine. When might we expect

12
00:00:35,120 --> 00:00:37,560
Speaker 2: to see it roll out and how quickly would you

13
00:00:37,640 --> 00:00:39,920
Speaker 2: expect that to actually show up in the price of eggs?

14
00:00:40,200 --> 00:00:42,080
Speaker 1: Sure, I mean what I want to start with is

15
00:00:42,120 --> 00:00:44,000
Speaker 1: just really that my heart goes out to all these

16
00:00:44,040 --> 00:00:47,040
Speaker 1: you know, producers, you know, both for boilers and egg layers.

17
00:00:47,240 --> 00:00:48,720
Speaker 1: You know, they've been on the front lines at this

18
00:00:48,760 --> 00:00:51,440
Speaker 1: crisis for a while now, and they've been doing everything

19
00:00:51,440 --> 00:00:54,840
Speaker 1: they can, through biosecurity and many other strategies to try

20
00:00:54,840 --> 00:00:57,760
Speaker 1: to control this, and Zoettas has been standing by and

21
00:00:57,800 --> 00:01:00,840
Speaker 1: supporting them. As we think about bio security as well

22
00:01:00,880 --> 00:01:03,760
Speaker 1: as diagnostics you know on farm with them align with

23
00:01:03,800 --> 00:01:07,119
Speaker 1: our purpose. So we were thrilled to get the conditional

24
00:01:07,200 --> 00:01:11,600
Speaker 1: license of our AI the product for poultry specifically, And

25
00:01:11,880 --> 00:01:14,039
Speaker 1: just to be clear, this is a conditional license that

26
00:01:14,200 --> 00:01:17,280
Speaker 1: is up to regulatory authorities in partnership with producers to

27
00:01:17,319 --> 00:01:19,960
Speaker 1: decide how and when to use, So the sole decision

28
00:01:19,959 --> 00:01:21,360
Speaker 1: on the use of the vaccine is up to the

29
00:01:21,480 --> 00:01:22,160
Speaker 1: US authorities.

30
00:01:22,280 --> 00:01:25,480
Speaker 2: Interesting, and I'm curious, you know what this means for

31
00:01:25,640 --> 00:01:28,080
Speaker 2: your business because, as we've spoken about before, you're more

32
00:01:28,080 --> 00:01:31,080
Speaker 2: heavily weighted to pets towards animals that we have in

33
00:01:31,120 --> 00:01:34,360
Speaker 2: our houses versus livestock. So with that in mind, I mean,

34
00:01:34,400 --> 00:01:37,520
Speaker 2: depending on the uptake, what could this mean for zoetas you.

35
00:01:37,480 --> 00:01:39,040
Speaker 1: Know for starters. But I think this is a great

36
00:01:39,080 --> 00:01:40,920
Speaker 1: example is what you and I spoke about at JP

37
00:01:41,000 --> 00:01:43,320
Speaker 1: Morgan just a few weeks ago, which is the strength

38
00:01:43,360 --> 00:01:47,200
Speaker 1: of our innovation pipeline across species. Well, we're expecting, you know,

39
00:01:47,280 --> 00:01:49,840
Speaker 1: a major approval every year for the next few years,

40
00:01:50,080 --> 00:01:53,480
Speaker 1: many of which will really be blockbusters in important categories

41
00:01:53,480 --> 00:01:57,680
Speaker 1: and animal health such as chronic kidney disease, on cology, cardiology,

42
00:01:58,000 --> 00:02:00,680
Speaker 1: you know, and antibiotic alternatives for life stuck, et cetera.

43
00:02:00,760 --> 00:02:03,040
Speaker 1: So we're really excited about that pipeline. We think this

44
00:02:03,120 --> 00:02:04,440
Speaker 1: is a great demonstration of that.

45
00:02:04,920 --> 00:02:06,560
Speaker 3: I don't want to get too far away from the

46
00:02:06,640 --> 00:02:09,600
Speaker 3: AV and flu. We spoke with the NEC director Kevin

47
00:02:09,680 --> 00:02:12,639
Speaker 3: Hassett about what's happened recently.

48
00:02:12,680 --> 00:02:13,639
Speaker 1: Listen to what he had to say.

49
00:02:14,520 --> 00:02:16,040
Speaker 4: What are we going to do about the fact that

50
00:02:16,120 --> 00:02:18,240
Speaker 4: Joe Biden last year killed one hundred and thirty million

51
00:02:18,320 --> 00:02:20,520
Speaker 4: chickens and that's why egg prices are so high? You know,

52
00:02:20,560 --> 00:02:23,360
Speaker 4: were putting together a plan to manage the AV and

53
00:02:23,400 --> 00:02:24,919
Speaker 4: flu in a much wiser way.

54
00:02:25,600 --> 00:02:27,360
Speaker 3: So he says, they were putting together a plan to

55
00:02:27,400 --> 00:02:29,200
Speaker 3: manage the AV and flu in a much wiser way.

56
00:02:29,320 --> 00:02:33,560
Speaker 3: Obviously a vaccine would be great for those animals who

57
00:02:33,600 --> 00:02:36,239
Speaker 3: haven't gotten it yet. But you also make drax in, right,

58
00:02:36,400 --> 00:02:40,480
Speaker 3: which is a drug that I'm not a doctor or

59
00:02:40,520 --> 00:02:44,680
Speaker 3: a vet, but somehow helps cows and swines with respiratory illnesses.

60
00:02:44,720 --> 00:02:47,440
Speaker 3: Are there other ways to deal with this problem or

61
00:02:48,080 --> 00:02:51,120
Speaker 3: do you really have to, you know, nip it in

62
00:02:51,160 --> 00:02:51,560
Speaker 3: the bud.

63
00:02:51,720 --> 00:02:53,640
Speaker 1: Sure, there's many ways to deal with this problem, and

64
00:02:53,680 --> 00:02:55,519
Speaker 1: I think you know, what Zoetis is focused on is

65
00:02:55,600 --> 00:02:58,640
Speaker 1: supporting our customers with a whole set of tools in

66
00:02:58,720 --> 00:03:01,080
Speaker 1: order to do this. What else talking about before is

67
00:03:01,280 --> 00:03:04,360
Speaker 1: really partnering with our producers to first start around biosecurity,

68
00:03:04,600 --> 00:03:07,520
Speaker 1: which they're focusing, you know, very intently on. But it

69
00:03:07,600 --> 00:03:09,440
Speaker 1: is a challenge when a lot of the new spread

70
00:03:09,480 --> 00:03:12,000
Speaker 1: you're seeing is spread by wild birds, and so you

71
00:03:12,040 --> 00:03:14,560
Speaker 1: can't really stop the wild birds from flying over your farm,

72
00:03:14,680 --> 00:03:16,440
Speaker 1: and that is really what is spreading some of the

73
00:03:16,480 --> 00:03:19,639
Speaker 1: new We can also focus on better diagnostics to better

74
00:03:19,720 --> 00:03:22,240
Speaker 1: understand that. There's lots of different tools in the toolbox,

75
00:03:22,440 --> 00:03:24,960
Speaker 1: you know. Obviously the vaccine is one additional one and

76
00:03:25,000 --> 00:03:27,400
Speaker 1: it's aligned with our purpose at Zoeti is to nurture

77
00:03:27,400 --> 00:03:30,120
Speaker 1: the world in humankind by advancing care for animals. And

78
00:03:30,120 --> 00:03:32,120
Speaker 1: that's a one health focus, which is I think what

79
00:03:32,200 --> 00:03:34,280
Speaker 1: the White House and the Congress and the USDA has

80
00:03:34,320 --> 00:03:35,040
Speaker 1: been really focused on.

81
00:03:35,080 --> 00:03:37,040
Speaker 5: And not to put the cart before the horror said

82
00:03:37,080 --> 00:03:39,160
Speaker 5: to speak. But you know, when you think about the

83
00:03:39,200 --> 00:03:41,400
Speaker 5: expansion of the vaccine, I recognize that you still need

84
00:03:41,400 --> 00:03:44,960
Speaker 5: regulatory approval, But what about other animals? Do you see

85
00:03:45,000 --> 00:03:46,360
Speaker 5: yourself making one for cattle?

86
00:03:47,040 --> 00:03:50,000
Speaker 1: You know, We've really stepped in in multiple crises over

87
00:03:50,040 --> 00:03:52,280
Speaker 1: the years. So we were helping the USDA with a

88
00:03:52,360 --> 00:03:54,920
Speaker 1: vaccine that they used in their stockpile bon in twenty sixteen.

89
00:03:55,200 --> 00:03:57,680
Speaker 1: As you think about the COVID crisis, we made vaccines

90
00:03:57,680 --> 00:04:00,320
Speaker 1: that were used throughout wildlife and in zoos and things

91
00:04:00,360 --> 00:04:02,480
Speaker 1: like that. So we will continue to partner with the

92
00:04:02,560 --> 00:04:04,800
Speaker 1: USDA to meet whatever their needs are.

93
00:04:05,440 --> 00:04:07,120
Speaker 2: I want to broaden out a little bit because you

94
00:04:07,160 --> 00:04:09,440
Speaker 2: mentioned your pipeline that you have coming up. There's a

95
00:04:09,440 --> 00:04:13,320
Speaker 2: lot of excitement over renal disease. For example, you think

96
00:04:13,320 --> 00:04:16,400
Speaker 2: about cats. You know, kidney diseases are really fatal to cats.

97
00:04:16,760 --> 00:04:19,800
Speaker 2: And like you said, I mean, you have big blockbusters

98
00:04:19,839 --> 00:04:21,880
Speaker 2: expected for the next couple of years. But then you

99
00:04:21,920 --> 00:04:23,480
Speaker 2: take a look at the stock price over a five

100
00:04:23,560 --> 00:04:26,039
Speaker 2: year basis, you're up about thirteen percent on a total

101
00:04:26,080 --> 00:04:29,359
Speaker 2: return basis. That compares to about fifty two percent for

102
00:04:29,520 --> 00:04:31,400
Speaker 2: your peer group. So with that in mind, what do

103
00:04:31,400 --> 00:04:34,520
Speaker 2: you think that shareholders are missing here about the story?

104
00:04:34,680 --> 00:04:37,240
Speaker 1: Yeah, we were thrilled to deliver double digit top and

105
00:04:37,279 --> 00:04:40,240
Speaker 1: bottom line performance for twenty twenty four and to give

106
00:04:40,279 --> 00:04:42,599
Speaker 1: an operational guide for this year. At the top line,

107
00:04:42,640 --> 00:04:46,160
Speaker 1: it's six to eight percent for organic operating growth. You know,

108
00:04:46,200 --> 00:04:47,760
Speaker 1: I think there was a little bit of a disconnect

109
00:04:47,760 --> 00:04:50,160
Speaker 1: with regards to foreign exchange for US, which was two

110
00:04:50,240 --> 00:04:52,200
Speaker 1: hundred and fifty million on the top line for US

111
00:04:52,200 --> 00:04:54,960
Speaker 1: in twenty twenty five fifty million on the bottom line,

112
00:04:55,120 --> 00:04:57,760
Speaker 1: as well as a divestiture for US of medicated feed

113
00:04:57,800 --> 00:05:00,000
Speaker 1: additives which is round three hundred and fifty five million

114
00:05:00,080 --> 00:05:01,920
Speaker 1: that need to be taken out. So we're working through

115
00:05:01,920 --> 00:05:03,919
Speaker 1: some of that, which we don't really believe was embedded

116
00:05:03,920 --> 00:05:06,440
Speaker 1: in the consensus as we saw last week. But we're

117
00:05:06,520 --> 00:05:10,440
Speaker 1: really confident that we've got multiple drivers of sustainable growth

118
00:05:10,600 --> 00:05:13,080
Speaker 1: in what is just a phenomenal industry and animal help

119
00:05:13,200 --> 00:05:15,279
Speaker 1: which has been incredibly resilient and durable.

120
00:05:15,480 --> 00:05:18,200
Speaker 3: What does the product makes look like if I look

121
00:05:18,240 --> 00:05:21,599
Speaker 3: over you know, just a list of your medicines. I

122
00:05:21,640 --> 00:05:26,120
Speaker 3: see obviously, dealing with parasites is first and foremost. Then

123
00:05:26,160 --> 00:05:29,640
Speaker 3: you've got like itchy skin problems, right, and then joint

124
00:05:29,640 --> 00:05:32,800
Speaker 3: issues like arthritis. Are those the three biggest categories?

125
00:05:32,920 --> 00:05:36,680
Speaker 1: Yeah, we've got multi billion dollar franchises and the biggest categories.

126
00:05:36,680 --> 00:05:39,800
Speaker 1: We've been driving double digit growth again, you know, in

127
00:05:40,000 --> 00:05:42,680
Speaker 1: categories such as paras and dermatology. They've been around for

128
00:05:42,720 --> 00:05:45,279
Speaker 1: more than a decade. So all these are billion dollar

129
00:05:45,360 --> 00:05:49,120
Speaker 1: franchises for US, the largest being parasiticides. You've got dermatology

130
00:05:49,160 --> 00:05:51,360
Speaker 1: where we've been in that market for over eleven years,

131
00:05:51,560 --> 00:05:55,080
Speaker 1: still last year driving seventeen percent growth. And then in

132
00:05:55,120 --> 00:05:57,719
Speaker 1: oa pain where we're really excited about the recent launch

133
00:05:57,720 --> 00:06:00,520
Speaker 1: in the US of Librella of cilensia, which has been

134
00:06:00,520 --> 00:06:03,120
Speaker 1: on the market in international for many years, and adding

135
00:06:03,120 --> 00:06:06,080
Speaker 1: to that over the coming years in renal, oncology, cardiology

136
00:06:06,080 --> 00:06:06,600
Speaker 1: excepta But.

137
00:06:06,520 --> 00:06:09,559
Speaker 3: By the way, do you produce all this stuff here?

138
00:06:09,600 --> 00:06:12,159
Speaker 3: Do you have overseas labs? I mean, the strong dollar

139
00:06:12,200 --> 00:06:13,320
Speaker 3: is that really an issue for you?

140
00:06:13,640 --> 00:06:15,839
Speaker 1: So the good news is we have a global network,

141
00:06:15,880 --> 00:06:18,480
Speaker 1: global supply chain. Our largest manufacturing sites are actually in

142
00:06:18,520 --> 00:06:22,400
Speaker 1: the United States. We also have some significant sites in Europe,

143
00:06:22,480 --> 00:06:24,880
Speaker 1: but the US is our primary manufacturing place for the

144
00:06:25,160 --> 00:06:27,599
Speaker 1: for Everyso so the dollar first, right, Well, the dollar

145
00:06:27,640 --> 00:06:28,880
Speaker 1: does well to that.

146
00:06:29,440 --> 00:06:31,440
Speaker 5: In fact, you're a CEO of a company, you want

147
00:06:31,440 --> 00:06:33,000
Speaker 5: to focus on your products, you want to focus on

148
00:06:33,040 --> 00:06:35,039
Speaker 5: your competition, you want to focus on getting new things

149
00:06:35,040 --> 00:06:37,320
Speaker 5: out there. How much do you have to think about

150
00:06:37,360 --> 00:06:40,480
Speaker 5: the strong dollar? Dynamic, particularly with all the tariff threats

151
00:06:40,520 --> 00:06:42,599
Speaker 5: out there, the riot higher in the dollar.

152
00:06:42,920 --> 00:06:45,440
Speaker 1: Look, our focus is living our purpose and meeting our

153
00:06:45,440 --> 00:06:48,240
Speaker 1: customer needs every day. We certainly are not experts in

154
00:06:48,240 --> 00:06:50,800
Speaker 1: foreign exchange, so our goal is to deliver for our

155
00:06:50,839 --> 00:06:54,839
Speaker 1: customers the products and solutions that they need. Obviously, we've

156
00:06:54,839 --> 00:06:57,920
Speaker 1: got teams who manage scenarios as you think about, you know,

157
00:06:57,960 --> 00:07:00,440
Speaker 1: for tariffs obviously, but we don't really make and day

158
00:07:00,440 --> 00:07:04,120
Speaker 1: to day foreign exchange are. We focus on living our purpose, all.

159
00:07:04,080 --> 00:07:05,919
Speaker 2: Right, Christin, that's a good place to leave it. Great

160
00:07:05,960 --> 00:07:08,360
Speaker 2: to speak to you today in studio. That is the

161
00:07:08,440 --> 00:07:11,760
Speaker 2: WEETA CEO Kristen Peck joining on the news that Zetas

162
00:07:11,800 --> 00:07:14,920
Speaker 2: has been granted a conditional license for its avian flu

163
00:07:15,000 --> 00:07:16,680
Speaker 2: vaccine from the USDA